Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridinyl)-4-(difluoromethoxy)-
| Title | Journal |
|---|---|
| Simultaneous quantitation of IC87114, roflumilast and its active metabolite roflumilast N-oxide in plasma by LC-MS/MS: application for a pharmacokinetic study. | Journal of mass spectrometry : JMS 20121201 |
| The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. | Diabetologia 20121001 |
| Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro. | British journal of pharmacology 20120801 |
| Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415 |
| Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. | British journal of pharmacology 20120301 |
| Roflumilast-N-oxide induces surfactant protein expression in human alveolar epithelial cells type II. | PloS one 20120101 |
| Pharmacokinetic evaluation of roflumilast. | Expert opinion on drug metabolism & toxicology 20111201 |
| Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study. | International journal of clinical pharmacology and therapeutics 20110801 |
| Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. | Journal of clinical pharmacology 20110401 |
| No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. | Journal of clinical pharmacology 20110401 |
| Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults. | Chronobiology international 20101001 |
| Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. | Clinical pharmacokinetics 20100901 |
| A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro. | Pulmonary pharmacology & therapeutics 20100801 |
| Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects. | British journal of clinical pharmacology 20091001 |
| The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions. | Journal of clinical pharmacology 20090401 |
| Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide. | International journal of clinical pharmacology and therapeutics 20090401 |
| Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide. | Journal of clinical pharmacology 20081101 |
| Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. | British journal of pharmacology 20071001 |
| Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. | Journal of clinical pharmacology 20070501 |
| Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis. | Clinical pharmacokinetics 20070101 |
| Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. | Clinical pharmacokinetics 20070101 |
| Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. | Journal of clinical pharmacology 20061001 |